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The Workshop Group on Epidemiology was asked to identify
weaknesses of current seroepidemiology studies that examine
the association of Chlamydiae pneumoniae with atherothrom-
botic diseases and to identify the potential for multidisciplinary
collaborative research at various levels. The group structured
this report according to the following categories: overall con-
cept, questions, measurement needs, informative populations,
trials, other proposals, and recommendations.
Overall Concept
We began by taking a broad view of the relationship between
C. pneumoniae infection and atherothrombotic diseases. A
model was used to express various components, such as deter-
minants and characteristics of infection, possible effect modi-
fiers, and various outcomes, both clinical and subclinical (figure
1). The model was designed to indicate significant gaps in our
knowledge.
As detailed in figure 1, the first stage of the model is “prein-
fection,” which may be influenced by host factors, environ-
mental factors, and other determinants of infection. The second
stage, “infection,” may be an incident, a reinfection, or per-
sistent (i.e., chronic active) infection. It also was noted that
there might be “other factors” that influence infection, includ-
ing genetic or noninfectious factors and other infections.
Another component of the model is “outcome.” The initial
outcome is subclinical atherosclerosis, which may or may not
progress to clinical events, such as myocardial infarction, coro-
nary heart disease death, and peripheral vascular disease. Un-
fortunately, most epidemiology studies have looked at the rela-
tionship of C. pneumoniae infection and late clinical athero-
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thrombotic diseases, leaving a dearth of studies looking at the
primary prevention of atherosclerosis, potential interactions of
C. pneumoniae with other risk factors, and additional high-risk
populations.
Questions
The workshop group began with a statement of critical epi-
demiologic questions that remain to be answered regarding the
association between C. pneumoniae infection and atherosclerosis:
1. What are the determinants of incident infection with C.
pneumoniae?
2. How do genetic factors relate to the response to infection
with C. pneumoniae?
3. Is progression of atherosclerosis associated with persistence
of infection or reinfection with C. pneumoniae?
4. Are there persons for whom it can be predicted that C.
pneumoniae infection is harmful and others in whom it is not?
5. How does the natural history of C. pneumoniae infection
relate to the natural history of atherosclerosis?
Measurement Needs
Group members generally agreed that there are a number of
deficiencies in serologic and other measurements that impede
further seroepidemiology studies:
1. The organisms being studied and the serologic and antigen-
detection methods used need to be standardized.
2. A means is needed for differentiating incident, reactivated,
and chronic infections.
3. Methods for the timing and collection of serial blood spec-
imens must be standardized, and more quantitative serology is
needed.
4. Methods for collecting peripheral blood monocytes to as-
sess chlamydial antigens must be standardized.
Other measurements that should be included in future epi-
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demiology studies examining the association between infection
with C. pneumoniae and atherothrombotic diseases include the
following:
1. Noninvasive measurements of atherosclerosis in different
vascular beds (e.g., coronary arteries, carotid arteries, adhesion
factors).
2. Intermediate or surrogate markers of inflammation and
adhesion molecules (e.g., inflammatory markers, acute-phase
reactants, cytokines, adhesion factors).
3. Other factors potentially related to both infection and
atherothrombotic diseases, such as lipids, dietary fat, and quan-
titative smoking measures (including measurements of early
exposure to passive smoking).
Informative Populations
There was a concern that population subsets of particular
interest have not been dealt with in past and current epide-
miology studies. In particular, it was felt that the following
population subsets should be considered in future studies:
1. Women.
2. Persons with high and low lipid levels.
3. Young adults (e.g., the Coronary Artery Risk Development
in Young Adults Study) and army recruits.
4. Children and adolescents (e.g., the ongoing cohort study
of childhood respiratory infections in Arizona).
5. Different ethnic groups (e.g., the Multi-Ethnic Study of
Atherosclerosis).
6. Immunosuppressed persons.
7. Persons with prior chronic lung disease.
Trials
The workshop group noted that the large ongoing secondary
prevention trials are excellent but do not deal comprehensively
with all at-risk persons and are restricted to late stages of ath-
erosclerosis. In particular, it was felt that there have been a
deficient number of studies regarding the primary prevention
of atherosclerosis, the selection of high-risk populations (as
classified on the basis of evidence of chronic persistent infec-
tion), and potential interactions with other risk factors. For
example, most trials are being conducted among middle-aged
and older adults, while studies of younger men and women are
needed to examine the effect of antibiotic treatment on the early
stages of atherosclerosis.
It was also felt that both epidemiology studies and prevention
trials should begin to define cohorts that would be suitable for
vaccine trials in the event that a C. pneumoniae vaccine is
developed.
Other Proposals
There was general agreement that epidemiology studies have
not sufficiently dealt with analysis of multiple factors (i.e., effect
modification). The problem here is that studies to date have
not had large enough sample sizes to do this. The solution
would be to pool data from databases from prior studies.
There was also discussion of the paradox that although most
international studies showed a remarkable uniformity of past
infection with C. pneumoniae, there did not seem to be an anal-
ogous uniformity in the prevalence of atherosclerosis in the
countries under study. Some panel members felt that further
international comparative studies are needed.
Recommendations
1. Further epidemiology studies regarding the association
between C. pneumoniae and atherothrombotic diseases would
benefit from a standardization of the means of measuring an-
tibodies and antigens (see Measurement Needs section).
2. Most epidemiology studies have been done with middle-
aged and older populations and in relation to clinical disease
end points of atherosclerosis, such as myocardial infarction and
coronary heart disease death. It is advised that epidemiology
studies be extended to additional populations (see Informative
Population section)
3. In regard to trials, the same concerns apply. The trials that
are being conducted are primarily using middle-aged and older
adults and are in relation to advanced stages of atherosclerosis,
which is a logical place to start. However, future studies should
extend to other populations, particularly women and younger
men and women in early stages of atherosclerosis (see Trials
section).
